192 related articles for article (PubMed ID: 27071708)
1. Molecular genetics and epigenetics of nonfamilial (sporadic) parathyroid tumours.
Westin G
J Intern Med; 2016 Dec; 280(6):551-558. PubMed ID: 27071708
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification.
Svedlund J; Koskinen Edblom S; Marquez VE; Åkerström G; Björklund P; Westin G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1307-15. PubMed ID: 22544915
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological correlates of hyperparathyroidism.
Duan K; Gomez Hernandez K; Mete O
J Clin Pathol; 2015 Oct; 68(10):771-87. PubMed ID: 26163537
[TBL] [Abstract][Full Text] [Related]
4. Genetics of parathyroid tumours.
Thakker RV
J Intern Med; 2016 Dec; 280(6):574-583. PubMed ID: 27306766
[TBL] [Abstract][Full Text] [Related]
5. The histone methyltransferase EZH2, an oncogene common to benign and malignant parathyroid tumors.
Svedlund J; Barazeghi E; Stålberg P; Hellman P; Åkerström G; Björklund P; Westin G
Endocr Relat Cancer; 2014 Apr; 21(2):231-9. PubMed ID: 24292603
[TBL] [Abstract][Full Text] [Related]
6. Global and gene-specific promoter methylation analysis in primary hyperparathyroidism.
Sulaiman L; Juhlin CC; Nilsson IL; Fotouhi O; Larsson C; Hashemi J
Epigenetics; 2013 Jun; 8(6):646-55. PubMed ID: 23764768
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic insights into sporadic primary hyperparathyroidism.
Brewer K; Costa-Guda J; Arnold A
Endocr Relat Cancer; 2019 Feb; 26(2):R53-R72. PubMed ID: 30475215
[TBL] [Abstract][Full Text] [Related]
8. Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.
Juhlin CC; Kiss NB; Villablanca A; Haglund F; Nordenström J; Höög A; Larsson C
PLoS One; 2010 Mar; 5(3):e9472. PubMed ID: 20208994
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors.
Björklund P; Akerström G; Westin G
J Clin Endocrinol Metab; 2007 Jan; 92(1):338-44. PubMed ID: 17047023
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathogenesis of primary hyperparathyroidism.
Arnold A; Shattuck TM; Mallya SM; Krebs LJ; Costa J; Gallagher J; Wild Y; Saucier K
J Bone Miner Res; 2002 Nov; 17 Suppl 2():N30-6. PubMed ID: 12412775
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.
Cardoso L; Stevenson M; Thakker RV
Hum Mutat; 2017 Dec; 38(12):1621-1648. PubMed ID: 28881068
[TBL] [Abstract][Full Text] [Related]
12. Analyzing Genetic Differences Between Sporadic Primary and Secondary/Tertiary Hyperparathyroidism by Targeted Next-Generation Panel Sequencing.
Hong YA; Park KC; Kim BK; Lee J; Sun WY; Sul HJ; Hwang KA; Choi WJ; Chang YK; Kim SY; Shin S; Park J
Endocr Pathol; 2021 Dec; 32(4):501-512. PubMed ID: 34215996
[TBL] [Abstract][Full Text] [Related]
13. An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/beta-catenin signaling.
Björklund P; Akerström G; Westin G
PLoS Med; 2007 Nov; 4(11):e328. PubMed ID: 18044981
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic alterations in human parathyroid tumors.
Verdelli C; Forno I; Vaira V; Corbetta S
Endocrine; 2015 Jun; 49(2):324-32. PubMed ID: 25722013
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathogenesis of parathyroid tumours.
Cinque L; Pugliese F; Salcuni AS; Scillitani A; Guarnieri V
Best Pract Res Clin Endocrinol Metab; 2018 Dec; 32(6):891-908. PubMed ID: 30477753
[TBL] [Abstract][Full Text] [Related]
16. Genetics and Epigenetics of Parathyroid Carcinoma.
Marini F; Giusti F; Palmini G; Perigli G; Santoro R; Brandi ML
Front Endocrinol (Lausanne); 2022; 13():834362. PubMed ID: 35282432
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid carcinoma: a clinical and genetic perspective.
Cetani F; Pardi E; Marcocci C
Minerva Endocrinol; 2018 Jun; 43(2):144-155. PubMed ID: 28949121
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry of cyclin D1 and beta-catenin, and mutational analysis of exon 3 of beta-catenin gene in parathyroid adenomas.
Ikeda S; Ishizaki Y; Shimizu Y; Fujimori M; Ojima Y; Okajima M; Sugino K; Asahara T
Int J Oncol; 2002 Mar; 20(3):463-6. PubMed ID: 11836555
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenesis of primary hyperparathyroidism.
Cetani F; Pardi E; Borsari S; Marcocci C
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):35-9. PubMed ID: 21985978
[TBL] [Abstract][Full Text] [Related]
20. Germline Mutations Related to Primary Hyperparathyroidism Identified by Next-Generation Sequencing.
Park HS; Lee YH; Hong N; Won D; Rhee Y
Front Endocrinol (Lausanne); 2022; 13():853171. PubMed ID: 35586626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
